PKN3 and pancreatic ductal adenocarcinoma: In 2014, Atu027, a lipid-based RNAi therapeutic aimed against the protein kinase N3 (PKN3) mRNA in the vascular endothelium to treat pancreatic ductal adenocarcinoma (PDAC), was well tolerated in a dose–escalation phase I clinical trial.